<ѻý>Most Older Women Do Not Meet Criteria to Stop Cervical Cancer Screeningѻý> Inadequate screening in middle age, lack of medical record documentation highlighted Jun 10, 2021
<ѻý>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care?ѻý> News, features, and commentary about cancer-related issues Jun 10, 2021
<ѻý>Bispecific Antibody Active in NRG1-Positive Pancreatic Cancerѻý> Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors Jun 10, 2021
<ѻý>Promising Early Data for Bladder-Sparing Cancer Treatmentѻý> Bladder-intact DFS at 1 year nears 90% for muscle-invasive bladder cancer Jun 09, 2021
<ѻý>TRK Inhibitor Proves Beneficial in Primary CNS Tumorsѻý> One-year OS rate with larotrectinib was 85% Jun 09, 2021
<ѻý>New Standard for Metastatic Castration-Sensitive Prostate Cancer?ѻý> Triplet regimen reduced the risk for radiographic progression or death, but OS data await Jun 09, 2021
<ѻý>More Support for Gene Assay to Guide Breast Cancer Treatmentѻý> More nuanced data on treatment de-escalation, extended endocrine therapy Jun 09, 2021
<ѻý>Another CAR-T Impresses in Follicular Lymphomaѻý> Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
<ѻý>BPAs Cut Fracture Risk in Metastatic Prostate Cancerѻý> Those receiving enzalutamide with and without radium-223 saw benefits in updated safety analysis Jun 08, 2021
<ѻý>Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patientsѻý> BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021
<ѻý>Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanomaѻý> But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
<ѻý>Combination Shows Promise in Post-Osimertinib Lung Cancerѻý> Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
<ѻý>Novel CDK 4/6 Inhibitor Proves Mettle in HR+/HER2- Advanced Breast Cancerѻý> Dalpiciclib may be a new treatment option; palbociclib and ribociclib continue to shine Jun 06, 2021
<ѻý>Perioperative Chemo Enough in Esophageal Cancer?ѻý> MAGIC/FLOT regimens yielded similar overall survival to multimodal CROSS regimen Jun 06, 2021
<ѻý>CAR-T Drives High Response in Relapsed/Refractory ALLѻý> ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit Jun 06, 2021
<ѻý>Antibody-Drug Conjugate Active in Resistant Lung Cancerѻý> Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
<ѻý>Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLCѻý> PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
<ѻý>Combination Therapy Achieves High Response in Ph+ ALLѻý> Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
<ѻý>Small PFS Bump in Synovial Sarcoma With Novel Drugѻý> But questions raised over control arm and whether improvement represents a meaningful benefit Jun 05, 2021
<ѻý>Radioligand Therapy Boosts Survival in Metastatic CRPCѻý> PSMA-directed agent improved overall survival by median 4 months Jun 04, 2021
<ѻý>Adding Chemo to Standard Care No Help for Cervical Cancerѻý> Similar OS, PFS, and patterns of recurrence, with more toxicity Jun 04, 2021
<ѻý>With Supplements, ADT in Prostate Cancer of Little Threat to Bone Densityѻý> Study suggests calcium/vitamin D alone sufficient for long-duration therapy Jun 03, 2021
<ѻý>PD-1 Inhibitor Shows Benefit in Nasopharyngeal Cancerѻý> Toripalimab plus first-line chemo improved survival in recurrent/metastatic disease Jun 03, 2021
<ѻý>Olaparib Wins in Early BRCA-Mutant Breast Cancerѻý> First trial to show adjuvant PARP inhibitor benefit inBRCA mutation carriers Jun 03, 2021
<ѻý>Survival Boost With First-Line Immunotherapy for Esophageal Cancerѻý> Nivolumab plus ipilimumab or chemo offers new option for advanced, metastatic disease Jun 03, 2021
<ѻý>'A Quantum Leap Forward': Potential New Standard in High-Risk RCCѻý> Adjuvant immunotherapy led to 32% reduction in the risk of recurrence, positive trend in OS Jun 03, 2021
<ѻý>Charles Grodin's Death From Multiple Myelomaѻý> A look at the beloved actor's highly treatable but rarely curable disease Jun 02, 2021
<ѻý>First-Line Chemo Plus Immunotherapy Falls Short in Bladder Cancerѻý> Adding pembrolizumab to cisplatin-based chemotherapy did not improve survival outcomes Jun 02, 2021
<ѻý>Radiation Speeds Up Biological Aging in Head and Neck Cancerѻý> Epigenetic age acceleration linked with greater inflammation and fatigue Jun 01, 2021
<ѻý>Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancerѻý> No improvement in overall survival when added to cisplatin-containing chemotherapy Jun 01, 2021
<ѻý>Drug to Delay T1D Gets Tepid Endorsement by FDA Advisorsѻý> Feelings mixed on safety and efficacy evidence for novel biologic May 28, 2021
<ѻý>Hospital at Home May Reduce Hospitalization, Costs for Cancer Patientsѻý> Study demonstrated efficacy, cost-effectiveness of providing hospital-level services at home May 26, 2021
<ѻý>Lymph Node Findings on PET: Cancer or COVID Vaccine?ѻý> Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<ѻý>Bad Day Sunshine: Benzene Found in Many Sun Care Productsѻý> Valisure also detected the carcinogen in hand sanitizers earlier this year May 26, 2021
<ѻý>Potassium Acid Blocker No Better Than PPI for Artificial Gastric Ulcersѻý> Small Japanese trial found similar outcomes with both drugs May 25, 2021
<ѻý>Op-Ed: A Door Opens to Transform Cancer Careѻý> Incoming CMS Administrator Chiquita Brooks-LaSure brings hope to the cancer community May 25, 2021
<ѻý>Family Alleges Profit Motives Played Role in 3-Year-Old's Deathѻý> Parents charge care delays for child with hydrocephalus were tied to arrangements for star doctor May 25, 2021
<ѻý>Test Can Predict Death Risk With Adrenal Tumorsѻý> This can help guide need for surgical intervention, researcher says May 24, 2021
<ѻý>Ovarian Cancer Screening Trial Still Sees No Death Reductionѻý> Researchers "disappointed" by long-term results of U.K. study of 200,000 postmenopausal women May 22, 2021
<ѻý>RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancersѻý> Responses to selpercatinib in almost half of tumors outside approved indications May 21, 2021